Name: UMIN ID:
Unique ID issued by UMIN | UMIN000015516 |
---|---|
Receipt number | R000017916 |
Scientific Title | Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer. |
Date of disclosure of the study information | 2014/11/01 |
Last modified on | 2019/07/17 10:33:57 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/10/24 09:48:27 | ||
2 | Update | 2015/01/05 15:45:01 | Organization Organization Category of Funding Organization Name of secondary funder(s) Name of secondary funder(s) |
|
3 | Update | 2015/04/27 16:45:20 | Email |
|
4 | Update | 2015/05/01 17:14:01 | Recruitment status Anticipated trial start date Last follow-up date |
|
5 | Update | 2015/05/07 10:03:38 | Email |
|
6 | Update | 2016/06/10 13:18:18 | Address Address Address Address Name of primary person or sponsor Organization |
|
7 | Update | 2016/10/25 09:15:02 | Last name of contact person Last name of contact person |
|
8 | Update | 2016/12/08 12:12:09 | Recruitment status |
|
9 | Update | 2018/11/01 15:54:09 | Last name of contact person Last name of contact person |
|
10 | Update | 2018/11/01 15:57:19 | Last name of contact person Last name of contact person |
|
11 | Update | 2019/06/16 01:47:35 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Email1 Organization Organization Address Address Tel |
|
12 | Update | 2019/07/17 10:32:21 | UMIN ID1 |
|
13 | Update | 2019/07/17 10:33:57 | Recruitment status Date of IRB |